DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Scott Harris - 3 Altimmune - 2 Eli Lilly - 2 Drugmakers Eli Lilly - 1 — - 1 Drugmaker Altimmune - 1 FierceBiotech - 1 Versanis - 1
Top related locs:
Altimmune GLP Altimmune's Novo Pittsburgh
Top related orgs:
Novo Nordisk - 2 Service - 1 Novo Nordisk's Ozempic - 1 Pittsburgh Pirates - 1 Detroit Tigers - 1 Pittsburgh - 1 The Pirates - 1 T Sportsnet - 1

Search resuls for: "Scott Harris"


5 mentions found


☆ A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug
  + stars: | 2024-03-29 | by ( Hilary Brueck | ) www.businessinsider.com   time to read: +3 min
A new GLP-1 drug, pemvidutide, helped patients lose fat while guarding muscle, like exercise does. That's impressive when you compare it to existing GLP-1 drugs like Ozempic and Wegovy (semaglutide), or Mounjaro and Zepbound (tirzepatide). This is why doctors recommend patients on weight loss drugs do some strength training in tandem with their medication. Pemvidutide, like tirzepatide is a two-part drug that combines a GLP-1 drug with another drug in a single shot. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss," Scott Harris, Altimmune's chief medical officer, said in a release.
Persons: Drugmakers Eli Lilly, —, Drugmaker Altimmune, Altimmune, Scott Harris, Eli Lilly, FierceBiotech, Versanis Organizations: Novo Nordisk, Service Locations: Altimmune, GLP
☆ Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
  + stars: | 2024-03-27 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Some health experts have said that obesity drugs could shrink critical muscle mass, which could raise the risk of injuries and decrease strength. Those results are similar to those often seen with diet and exercise programs for weight loss. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss." For example, Eli Lilly is testing whether combining its weight loss drug with a monoclonal antibody from Versanis Bio might help patients lose weight while preserving muscle mass. The pharmaceutical giant recently acquired Versanis, which is part of a slate of companies targeting the muscle-loss aspect of weight loss.
Persons: Altimmune, Eli Lilly, Scott Harris Organizations: Novo Nordisk, Novo Nordisk's Ozempic Locations: Altimmune's, Novo
☆ After trading vets, young Pirates try to beat Tigers again
  + stars: | 2023-08-02 | by ( Field Level Media | ) www.reuters.com   time to read: +4 min
August 2 - Life after the major league trade deadline is here for the Pittsburgh Pirates and visiting Detroit Tigers. Pittsburgh rookies Endy Rodriguez, Jared Triolo, Liover Peguero and Alika Williams combined to go 5-for-12. "We've got to focus on what we can control, which is trying to play more competitive baseball and win more games," Tigers manager A.J. One thing the Tigers have to look forward to is designated hitter Miguel Cabrera's climb up the record books. He raised his total to 3,138 career hits, three shy of tying Tony Gwynn for 21st place in major league history.
Persons: Endy Rodriguez, Jared Triolo, Liover, Alika Williams, Peguero, Rodriguez, Williams, Triolo, We're, Nick Gonzales, Henry Davis, Carmen Mlodzinski, Jose Hernandez, it's, you've, Austin Hedges, Rich Hill, Rodolfo Castro, Ji Man Choi, Carlos Santana, Michael Lorenzen, We've, A.J, Hinch, Miguel Cabrera's, Cabrera, Tony Gwynn, Gwynn, Robin Yount, Paul Waner, George Brett, Eduardo Rodriguez, Osvaldo Bido, Scott Harris, Eduardo, Bido, Ryan Borucki, Borucki Organizations: Pittsburgh Pirates, Detroit Tigers, Pittsburgh, The Pirates, T Sportsnet, Detroit, Tigers, Los Angeles Dodgers, Los Angeles Angels, Pirates, Angels, Thomson Locations: Pittsburgh
☆ Altimmune's obesity drug safety concerns shrink shares
  + stars: | 2023-03-21 | by ( Bhanvi Satija Sriparna Roy | Bhanvi Satija | Sriparna Roy | ) www.reuters.com   time to read: +2 min
March 21 (Reuters) - Altimmune Inc's (ALT.O) experimental obesity drug helped reduce weight by over 10% on average in a mid-stage trial, the company said on Tuesday, but safety concerns sent its shares tumbling more than 50%. Wolleben added that the drug showed " a little bit worse" tolerability than previous data. Patients who received a 2.4 milligram dose of Altimmune's experimental drug, pemvidutide, achieved average weight loss of 10.7% at the end of week 24, the company said. The data looked competitive to mid-stage data from Novo Nordisk's (NOVOb.CO) obesity drug Wegovy and Eli Lilly's (LLY.N) candidate for the condition, most analysts said. While Novo Nordisk's drug Wegovy is already available, Lilly expects approval for its obesity drug candidate, tirzepatide, this year.
☆ Looking for a ‘Real’ Two-Bedroom in Manhattan or Brooklyn. Which Borough Offered More for Their Money?
  + stars: | 2022-10-20 | by ( Debra Kamin | ) www.nytimes.com   time to read: +2 min
Ms. Gaither, 31, who grew up in Akron, Ohio, and has lived in New York for over a decade, is a recruiter at Google. “I was team Brooklyn and he was team Manhattan,” Ms. Gaither said. Ms. Gaither, who prefers older buildings, was undeterred by the prospect of a small renovation, and was partial to several areas in Brooklyn. “We were elder millennials in Williamsburg, with warring rooftop DJs starting at 2 p.m. every Saturday,” Ms. Gaither said. The couple has a 3-year-old rescue dog, Sadie, and during the pandemic Ms. Gaither began fostering dogs, as well.
0 next >>
Total: 5